-
NMN can improve diabetic nephropathy by up-regulating BMP7
May , 26 2021
Diabetic nephropathy is one of the most common chronic complications of diabetes, and its incidence is also on the rise. It has become the second cause of end-stage renal disease, second only to vario...
read more
-
Prevent heart failure and supplement NMN to improve heart function as a new idea
Dec , 07 2021
Research published in the SCI journal "Journal of Molecular and Cellular Cardiology" by the scientific research team of the Cleveland Medical Center in the United States shows that: Supplementing NAD+...
read more
-
Market Overview of Lycopene
Jul , 18 2022
Lycopene has been widely used in many popular fields such as oral beauty, cardiovascular health, antioxidant, men's health, eye protection, brain health, etc. It is a hot functional food raw material,...
read more
-
Advantages of astaxanthin industry in China
May , 22 2023
China is one of the largest producers and exporters of astaxanthin in the world. The country has a well-established astaxanthin industry and is known for its production of this natural pigment. In Chi...
read more
-
Sinoway publishs product list for CPhI China 2023
Jun , 16 2023
CPhI China 2023 will be held in Shanghai on Jun.19-21, 2023. In Jun. 15, Sinoway published the product list for this exhibition. Please click the button below to get the latest products. We Sinoway si...
read more
-
Semaglutide's Market Prospects in the Global Pharmaceutical Industry
Apr , 29 2024
Semaglutide, as a GLP-1 class drug, holds a prominent position in the global pharmaceutical market, especially in light of the ongoing obesity epidemic. Its significance was underscored when it topped...
read more
-
China announces anti-aging NMN human clinical trial results: the physiological age of the NMN supplement group was significantly reduced！
May , 10 2024
On the morning of April 27, LEGEND Vascular Symposium 2024 was grandly held in Shanghai. At the meeting, the unblinded results of the anti-aging β-Nicotinamide Mononucleotide (short for NMN) , a human...
read more
-
Semaglutide in China: Advancements in Production, Quality, and Competitive Pricing
Jul , 25 2024
Semaglutide (CAS No: 910463-68-2) belongs to the class of GLP-1 receptor agonists and is used both as an antidiabetic for treating type 2 diabetes and as an anti-obesity medication for long-term weigh...
read more
-
Semaglutide: Play an important role in Global Weight Loss Market
Sep , 04 2024
Semaglutide, a GLP-1 receptor agonist, is revolutionizing the management of type 2 diabetes and weight loss. It's available in injectable and oral forms, marketed as Ozempic, Rybelsus for diabetes, an...
read more
IPv6 network supported
English
中文
français
Deutsch
русский
español
português
العربية
日本語
한국의
Türkçe
